Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Systemic gamma-interferon therapy for recurrent gliomas.

M S Mahaley1, L Bertsch, S Cush

  • 1Division of Neurological Surgery, University of Alabama, Birmingham.

Journal of Neurosurgery
|December 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of immunologic parameters in canine glioma patients treated with an oncolytic herpes virus.

Journal of translational genetics and genomics·2022
Same author

KLF6 depletion promotes NF-κB signaling in glioblastoma.

Oncogene·2017
Same author

γ₁34.5-deleted HSV-1-expressing human cytomegalovirus IRS1 gene kills human glioblastoma cells as efficiently as wild-type HSV-1 in normoxia or hypoxia.

Gene therapy·2015
Same author

γ₁34.5-deleted HSV-1-expressing human cytomegalovirus IRS1 gene kills human glioblastoma cells as efficiently as wild-type HSV-1 in normoxia or hypoxia.

Gene therapy·2014
Same author

Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell lines.

Gene therapy·2014
Same author

Increased oncolytic efficacy for high-grade gliomas by optimal integration of ionizing radiation into the replicative cycle of HSV-1.

Gene therapy·2011

Recombinant gamma-interferon showed limited efficacy in treating recurrent gliomas, with only one patient responding and three experiencing stabilization. Toxicity was also observed in this study of recurrent brain tumors.

Area of Science:

  • Neuro-oncology
  • Immunotherapy
  • Recombinant protein therapy

Background:

  • Recurrent gliomas present a significant therapeutic challenge.
  • Limited treatment options exist for patients with recurrent gliomas.
  • Gamma-interferon is being investigated for its potential anti-tumor effects.

Purpose of the Study:

  • To evaluate the efficacy and safety of recombinant gamma-interferon in patients with recurrent gliomas.
  • To assess treatment response using computerized tomography (CT).

Main Methods:

  • Fourteen patients with recurrent gliomas received intravenous recombinant gamma-interferon (2 mg/sq m) twice weekly for 8-week courses.
  • Patients had relatively small initial tumor volumes (<50 cu mm on enhanced CT) and Karnofsky ratings (≥70).

Related Experiment Videos

Main Results:

  • Computerized tomography (CT) evidence of response was observed in only one patient.
  • Tumor stabilization was recorded in three patients, lasting 12 to 86 weeks.
  • Several instances of toxicity potentially related to gamma-interferon were noted.

Conclusions:

  • Recombinant gamma-interferon demonstrated disappointing efficacy in this patient cohort with recurrent gliomas.
  • The observed toxicity warrants careful consideration in future therapeutic strategies.
  • Further research may be needed to explore alternative immunotherapies or combination treatments for recurrent gliomas.